Stock Code 688278
中文 EN

ABOUT US

Xiamen Amoytop Biotech Co., Ltd.

Xiamen Amoytop Biotech Co., Ltd. is an innovative biopharmaceutical company in China, specialized in R&D, manufacturing and marketing of regular and long-acting recombinant protein drugs. Focusing on the R&D of immune-related cytokine medicines, Amoytop Biotech is committed to becoming a leader in solving cytokine medicine-based systemic immune problems, providing better solutions for major diseases (such as viral hepatitis, malignant tumors) and immunotherapy. Currently, Amoytop Biotech is specially focusing on CHB (chronic hepatitis B) treatment aiming to achieve breakthroughs in clinical cure of CHB.

Targeting major diseases and immunotherapy fields, Amoytop Biotech has built an innovation platform covering the expression, long-acting modification and industrialization of various protein drugs, and owned the innovation ability in fundamental research, pilot-scale research, clinical study and industrialization research. Now,and been awarded as a national innovation-oriented enterprise which has advantages in national intellectual property. Keeping the global market in mind, Amoytop Biotech spares every effort to explore international markets based on the domestic market. Up to now, Amoytop Biotech has marketed its products in South-East Asia, South America and CIS area. Through technical innovation, scientific management and product industrialization, Amoytop Biotech aims to gradually become a leading international biopharmaceutical company in China.

  • 1

    National innovation team in priority area

  • 4

    Launched drug products

  • 9

    National Major Scientific and Technological Special Projects for Significant New Drug Development

  • 12

    Patents

After 14-year development, the long-acting interferon drug product of Amoytop Biotech, Pegberon® (pegylated interferon alfa-2b), national class-1 new drug, was approved in China in 2016. Pegberon is the first 40kD Y-shape branched PEG modified interferon alfa-2b injection in the world, with special structure in complete patent protection, has broken the monopoly of foreign products in treatment of viral hepatitis, and awarded with “2016 Top 10 China Medicinal Biotech Progress” by China Medicinal Biotechnology Association.

Recently, with the idea of “clinical cure” in chronic hepatitis B treatment filed has been gradually recognized by hepatitis specialists and clinicians, Amoytop Biotech has supported/conducted a series of research projects aiming to improve CHB clinical cure level, including CHB clinical cure projects listed in the National Major Scientific and Technological Special Projects during the “13th Five-year Plan” period, exploratory researches on the application and optimization of chronic hepatitis B clinical cure, and relevant confirmatory clinical trials. Through continuous exploration and accumulation, Amoytop Biotech is devoted to be the leader in CHB clinical cure field based on pegylated interferon alfa-2b.

Pegberon

COMPANY CULTURE

Company Culture

  • 01

    Vision

    Devoted to Constant Innovation in Biopharmaceutical Field for a Better and Healthier Life for Human

  • 02

    Mission

    To be a Leading International Biopharmaceutical Company in China

  • 03

    Core Value

    Responsibility丨Fairness丨Performance丨Win-Win

DEVELOPMENT PATH

Milestones

1996

1997

1999

2002

2004

2005

2008

2010

2011

2012

2014

2016

2020

1996

 Founded Amoytop Biotech

1997

Launched TOPLEUCON® (rHuGM-CSF), the first China-made GM-CSF

1999

Launched TOPNEUTER® (rHuG-CSF)

2002

Founded wholly-owned research institute,“Xiamen Biosteed Gene Transformation Tech. Co. ,Ltd.”

2004

Undertook the Demonstration Project of Industrialization and Internationalization of Genetically Engineered Protein Drugs for National Development and Reform Committee, China

2005

Launched TOPMEGA® (rHuIL-11)

2008

Established postdoctoral research station

2010

Awarded“NationalInnovation-Oriented Enterprise”

2011

Approved as“National-Local Joint Research Center”

2012

Approved as“National Torch Program Key High-Tech Enterprises”

2014

Approved as “National Innovation Team in Priority Fields” by Ministry of Science and Technology

2016

Launched PEGBERON® (Peginterferon alfa-2b),national class 1 new drug

2020

Listed on SSE STAR Market (Sci-tech innovation board, Shanghai Stock Exchange), the first biomedical stock from Fujian Province

HONORARY

Awards and Honors

Postdoctoral research station

National Innovation-Oriented Enterprise

National-Local Joint Research Center

Key High-Tech Enterprises of National Torch Program

China National Accreditation Service for Conformity Assessment (CNAS) certificate

RESPONSIBILITY

Social Responsibility

Realizing “the value of technology and knowledge by transforming technology and knowledge into products to benefit patients” is the initial mission and intention having been insisted on by Amoytop Biotech. As a pharmaceutical enterprise, Amoytop Biotech takes promoting the development of biomedical industry and providing healthier life for more patients as its main social responsibility.
  • Tel:86 592 6889105/108

    Email: bd.amoytop@gmail.com / international@amoytop.com

    Add:No. 330 Wengjiao Road, Haicang, Xiamen, Fujian, China

  • Join Us:0592-7701210

    Email:hr@amoytop.com

  • Adverse Events Tel:86-592-6889111

    Adverse Events Email:fk@amoytop.com